Biotech Archives - Page 54 of 795

3 minute read

FDA Approves Biktarvy Label Update With Data For Pregnant Adults With HIV; Perinatal Guidelines Recognize Biktarvy As Alternative Regimen For Use During Pregnancy And For Those Trying To Conceive

April 26, 8:05 AM

– Additional Data in Pregnant Adults Who Are Virologically Suppressed Reinforce Safety and Tolerability Profile of Biktarvy in Broad Range of People With HIV –– Perinatal Guidelines Recognize Biktarvy as Alternative

GILD

1 minute read

Adverum Biotechnologies To Present LUNA 26-Week Phase 2 Interim Analysis At The ASRS Annual Scientific Meeting

By Benzinga Newsdesk

April 25, 4:40 PM

Adverum Biotechnologies, Inc. (NASDAQ:ADVM), a clinical-stage company pioneering the use of gene therapy as a new standard of care for highly prevalent ocular diseases, today announced that the company will present the

ADVM

2 minute read

Aligos Therapeutics Presents Clinical Data At ESCMID 2024 From The ALG-097558 Phase 1 Study

By Benzinga Newsdesk

April 25, 4:26 PM

Data demonstrates a 7-day treatment regimen with the pan-coronavirus protease inhibitor ALG-097558 was well tolerated and does not require ritonavir boostingSOUTH SAN FRANCISCO, Calif., April 25, 2024 (GLOBE NEWSWIRE) --

ALGS

2 minute read

AbbVie’s Dermatitis Drug Shown ‘Superior’ To Sanofi/Regeneron’s Dupixent In Head-To-Head Study

By Vandana Singh

April 25, 1:58 PM

AbbVie's Upadacitinib outperforms dupilumab in Phase 3b/4 study for atopic dermatitis treatment, achieving superior efficacy and rapid skin clearance than Dupixent.

ABBV

2 minute read

What’s Going On With Pfizer Stock On Thursday?

By Vandana Singh

April 25, 1:51 PM

GSK initiates legal proceedings against Pfizer and BioNTech over alleged COVID-19 vaccine patent infringement, intensifying high-stakes legal battles in the U.S.

BNTX

2 minute read

Bristol Myers Squibb Swings To Quarterly Loss, After String Of Multi-Billion Acquisitions

By Vandana Singh

April 25, 12:23 PM

Discover Bristol Myers Squibb's impressive first-quarter performance, with revenues exceeding expectations driven by key products like Eliquis and Reblozyl. Despite challenges, the company aims for significant cost savings and future growth.

BMY

2 minute read

Tiziana Life Sciences Reports 3-Month Neuroimaging Scores In Multiple Sclerosis Patients Receiving Intranasal Foralumab; A Primary Endpoint With Clinical Measures Of EDSS (Disability) And MFIS (Fatigue) Is Currently Underway

By Benzinga Newsdesk

April 25, 10:01 AM

Tiziana Life Sciences, Ltd. (NASDAQ:TLSA) ("Tiziana" or the "Company"), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announced for the first time,

TLSA

2 minute read

Drugmaker Sanofi’s Strong Dupixent And Beyfortus Vaccine Sales Propel Q1 Earnings

By Vandana Singh

April 25, 9:47 AM

Sanofi reports Q1 operating income at 2.8 billion euros, down 14.7%. Beat consensus EPS at $0.97. Sales reach $11.36 billion, led by Dupixent's 24.9% surge. Vaccine sales up 5.6%. Expecting Dupixent to hit €13 billion in 2024 sales. Blockbuster ambitions for Beyfortus.

SNY

2 minute read

Aclarion’s Nociscan Solution To Play Key Role In LIFEHAB Trial Evaluating The Diagnosis And Treatment Of Chronic Low Back Pain

By Benzinga Newsdesk

April 25, 9:20 AM

LIFEHAB is a randomized controlled trial in Norway comparing lumbar interbody fusion surgery with multidisciplinary rehabilitationNorway is a single-payer national health insurance systemLIFEHAB is targeting enrollment

ACON

2 minute read

AstraZeneca Posts Bumper Earnings On Strong Sales From Cancer Drugs, Sticks To Annual Guidance

By Vandana Singh

April 25, 9:03 AM

AstraZeneca reports Q1 sales of $12.68 billion, up 17% Y/Y. Despite missing adjusted EPADS, oncology sees a 26% surge, driven by Tagrisso and Imfinzi. Cardiovascular sales up 20%. R&D up 18%. Fiscal 2024 outlook: low double-digit revenue and EPS growth.

AZN